NCT07212335View on ClinicalTrials.gov

Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Immune Effector Cell Associated Hematotoxicity
Interventions
BIOLOGICAL

Mesenchymal Stem Cell Infusion

Mesenchymal stem cells: intravenous infusion, 2×10⁶ cells/kg body weight/week (once weekly), with 1 to 4 administrations based on different dosage groups.

Trial Locations (1)

300020

Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology), Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER